Leaderboard
Anzeige
medline.ch
En
|
De
Impressum
No articles selected!
View Cart
You are here:
Oncology
»
Urologic Neoplasms
06. October 2026
Search
medline.ch
Urologic Neoplasms
Advanced search
Dermatology
Endocrinology
Nutrition
Gastroenterology
Gynecology
Haematology
Infectious diseases
Cardiovascular Diseases
Musculoskeletal Diseases
Neurology
Oncology
Musculoskeletal System
Blood
Endocrine System
Gynecologic Neoplasms
Skin
Gastrointestinal
ORL
Respiratory Tract
Urologic Neoplasms
CNS
ORL
Pediatrics
Psychiatry
Respiratory Tract
Sports
Urology-Nephrology
Rect Top
Anzeige
Zoom:
Page 1 of 9098
Articles 1 - 20 / 181948
Re: Philip Cornford, Roderick C.N. van den Bergh, Erik Briers, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2026 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2026.04.013.
Eur Urol
Stabile A, Quarta L, Scilipoti P, Dehň F, Briganti A, Montorsi F.
PMID: 42833933 [PubMed - as supplied by publisher]
Efficacy and Safety of Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Non-BRCA Mutation Subgroup of Patients with Metastatic Castration-resistant Prostate Cancer in the PROpel Trial.
Eur Urol Oncol
Mehra N, Clarke NW, Armstrong AJ, Oya M, Shore N, Procopio G, Guedes JD, Arslan C, Brown E, Joung JY, Sugimoto M, Choi YD, Castellano D, Ürün Y, Hosius C, McGuinness D, Degboe A, Saad F.
PMID: 42833926 [PubMed - as supplied by publisher]
Two-stage high-frequency ultrasonic characterization of ex vivo renal tumor microstructure.
Ultrasound Med Biol
Zuluaga L, Gleed AD, Bamby J, Okhawere KE, Levieddin J, Ucpinar B, Ucpinar BA, Hoerig C, Mamou J, Badani KK.
PMID: 42833906 [PubMed - as supplied by publisher]
Testosterone breakthrough and outcomes during intensified therapy in metastatic hormone-sensitive prostate cancer: the ARASENS and LATITUDE trials.
BJU Int
Xiao X, Ni X, Zhao Y, Li X, Wang S, Wang H, Ye D, Wu J, Zhu Y.
PMID: 42833883 [PubMed - as supplied by publisher]
Integrated computational framework for drug repurposing in metastatic prostate cancer using transcriptomic meta-analysis, machine learning, and molecular modeling.
Comput Biol Chem
Rafiee J, Arabi Baygi ST, Aghaee-Bakhtiari SH.
PMID: 42833027 [PubMed - as supplied by publisher]
Explainable Machine Learning-Based Prediction of Progression-Free Survival in Prostate Cancer: Retrospective Cohort Study.
JMIR Cancer
Tun HM, Naing L, Malik OA, Abdullah MS, Ta T, Rahman HA.
PMID: 42832781 [PubMed - indexed for MEDLINE]
Leveraging Artificial Intelligence to Monitor Patients With Prostate Cancer in a Retrospective Cohort of Radiation Oncology Clinic Patients.
Clin J Oncol Nurs
Boyajian RN, Hagen M, Bagchi S, Mahatma S, Kowtoniuk A, Trinh QD, Kumar T, Nguyen PL.
PMID: 42832322 [PubMed - indexed for MEDLINE]
Full-Field Optical Coherence Tomography for Immediate Analysis of Prostate Biopsy Cores: A New Step toward Real-Time Cancer Diagnosis.
Ann Surg Oncol
Anract J, Chen W, Duquesne I, Larnaudie L, Diamand R, Sibony M, Barry Delongchamps N.
PMID: 42832144 [PubMed - as supplied by publisher]
Targeted pelvic lymph node dissection using magnetic resonance imaging - ultrasonography fusion technique and indocyanine green injection in robot-assisted radical prostatectomy.
J Robot Surg
Yamada Y, Kimura N, Hakozaki Y, Nakamura M, Sugano K, Sugimoto K, Kakutani S, Miyakawa J, Kamei J, Niimi A, Taguchi S, Kume H.
PMID: 42832079 [PubMed - indexed for MEDLINE]
The effect of ureteral stenting on the risk of metachronous upper tract urothelial carcinoma in patients with bladder tumors involving the ureteral orifice.
World J Urol
Pyrgidis N, Engelmann P, Puhr-Westerheide D, Ebner B, Kidess M, Semmler M, Keller P, Stief C, Schulz GB, Volz Y.
PMID: 42832054 [PubMed - indexed for MEDLINE]
Partial vs. whole-gland salvage hifu after radiotherapy failure: oncological and functional outcomes.
World J Urol
Maillard C, Mebroukine S, Haaser T, Pasticier G, Robert G, Bladou F.
PMID: 42831949 [PubMed - indexed for MEDLINE]
A Clinical Insight into Von Hippel-Lindau Syndrome: Diagnostic Challenges.
Prague Med Rep
Rosado GAC, da Cunha AC, Duarte ML, de Abreu VMG.
PMID: 42831607 [PubMed - indexed for MEDLINE]
PRECISE Assessment of Sequential Biparametric MRI and Clinically Significant Prostate Cancer in Biopsy-naive Men: A Retrospective Cohort Study.
Eur Urol Open Sci
Tian Y, Liu Z, Chen S, Zhou Y, Ruan M, Li D, Wu J, Fan Y, Liu Y.
PMID: 42831142 [PubMed]
Incidence, Patterns, and Predictive Factors of Biochemical Failure Following Definitive Radiotherapy for Localized Prostate Cancer: A Retrospective Military Cohort Study.
Cureus
Alnajada W, Ghnmein NM, Ayyad R, Abukaff A, Bani Essa M, Alhabahbeh L, Daheerat AN, Alzyoud A, Alhiary Z.
PMID: 42829772 [PubMed]
Recent Advances in Cyclic Peptide-Based Therapeutic Strategies for Renal Cell Carcinoma: A Focused Review.
Drug Des Devel Ther
Sun L, Li X, Liu Y, Wu G.
PMID: 42829760 [PubMed - indexed for MEDLINE]
Exploring regulated cell death in renal cell carcinoma: mechanistic insights and therapeutic perspectives.
Apoptosis
Zhu G, Zhang H, Li Y, Ma W, Yao Y, Lyu D, Lu B, Zong Y, Dong K, Zhou W, Liu Y, Cui X, Pan X.
PMID: 42829358 [PubMed - indexed for MEDLINE]
Re: Sobia Khan, Nathan Papa, Andrew Kneebone, et al. Prospective Comparison of (64)Copper [(64)Cu]SAR-bisPSMA vs (68)Gallium [(68)Ga] PSMA-11 PET/CT for Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy (Co-PSMA Trial). Eur Urol 2026;89:512-20.
Eur Urol
Hindié E, Callaud A, Morgat C.
PMID: 42829270 [PubMed - as supplied by publisher]
Reply to Paolo Zaurito's Letter to the Editor re: Robert M. Meier, Nima Aghdam, Alan C. Beckman, et al. 10-yr Survival and Toxicity Outcomes of Stereotactic Body Radiotherapy for Prostate Cancer: A Nonrandomized Clinical Trial. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.04.029.
Eur Urol
Meier R, Aghdam N, Kaplan I.
PMID: 42829268 [PubMed - as supplied by publisher]
Reply to Riccardo Lombardo's Letter to the Editor re: Bi-Ming He, Keqin Zhang, Zhien Zhou, et al. Cognitive Versus Software-based Fusion targeted Biopsy for the Diagnosis of Clinically Significant Prostate Cancer: A Multicenter, Randomized, Noninferiority Trial (IMAGINATION). Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.06.020.
Eur Urol
He BM, Wang HF.
PMID: 42829267 [PubMed - as supplied by publisher]
PSMA-PET/CT-guided Intensification of Radiation Therapy for Prostate Cancer (PSMAgRT): 5-yr Analysis of a Phase 2 Randomized Controlled Trial.
Eur Urol
Belliveau C, Saad F, Duplan D, Petit C, Delouya G, Lambert C, Taussky D, Barkati M, Beauchemin MC, Clavel S, Mok G, Gauthier-Paré AS, Igidbashian L, Jolicoeur M, Nguyen TV, McLaughlin PY, Wong P, Keu KV, DaSilva JN, Juneau D, Ménard C.
PMID: 42829266 [PubMed - as supplied by publisher]
Articles 1 - 20 / 181948
Page 1 of 9098
Rect Bottom
Anzeige
Adserver Footer
Time frame
--unlimited--
1 Week
1 Month
3 Months
6 Months
1 Year
2 Years
3 Years
5 Years
10 Years
Sky right 1
Anzeige
Mediscope AG E-mail:
info@mediscope.ch
Disclaimer
|
Privacy Policy